Skip to main content
SpringerLink
Log in
Book cover

Psychiatry Under the Influence pp 87–115Cite as

Palgrave Macmillan

Expanding the Market

  • Chapter

  • 430 Accesses

Abstract

Once pharmaceutical companies obtained FDA approval for their new psychiatric medications, they naturally wanted to maximize the sale of their products. This meant expanding the pool of potential patients, and to do this, the companies needed the assistance of academic psychiatry and the American Psychiatric Association (APA). From the drug companies’ perspective, the business model to be pursued was obvious: They could provide the financial resources for this task, while academic psychiatry and the APA provided the medical legitimacy. This legitimacy, industry knew, could originate with the DSM: The APA could expand the pool of potential patients by creating new diagnoses or by loosening the diagnostic criteria for existing diagnoses, and then industry could hire academic psychiatrists to conduct studies of the drugs for these new patient populations. Then industry could hire those same psychiatrists, or others in academia, as “key opinion leaders” to speak at professional conferences about the validity of the “illness” and the helpful drug treatment.

Like knowledge itself, diagnostic language confers power, but that power is not necessarily benign.

—Jeanne Maracek, 19931

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Notes

  1. J. Maracek. “Disappearances, silences and anxious rhetoric: gender in abnormal psychology textbooks.” J Theor Philos Psychol 13 (1993): 114–23.

    Article  Google Scholar 

  2. J. Biederman. “Attention-deficit/hyperactivity disorder: a life-span perspective.” J Clin Psychiatry 59, suppl. 7 (1998): 4–16.

    Article  Google Scholar 

  3. M. Strand. “Where do classifications come from? The DSM-III, the transformation of American psychiatry, and the problem of origins in the sociology of knowledge.” Theor Soc 40 (2011): 273–313.

    Article  Google Scholar 

  4. L. Cosgrove. “Financial ties between DSM-IV panel members and the pharmaceutical industry.” Psychother Psychosom 75 (2006): 154–60.

    Article  Google Scholar 

  5. R. Kessler. “Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.” Arch Gen Psychiatry 62 (2005): 617–27.

    Article  Google Scholar 

  6. R. Mayes. Medicating Children (Cambridge, MA: Harvard University Press, 2009): 46.

    Google Scholar 

  7. B. Lahey. “DSM-IV field trials for attention deficit hyperactivity disorder in children and adolescents.” Am J Psychiatry 151 (1994): 1673–85.

    Article  Google Scholar 

  8. S. Faraone. “Is attention deficit hyperactivity disorder familial?” Harv Rev Psychiatry 1 (1994): 271–87.

    Article  Google Scholar 

  9. T. Wilens. “Attention-deficit hyperactivity disorder and comorbid substance use disorder in adults.” Psychiatr Serv 46 (1995): 761–3.

    Article  Google Scholar 

  10. T. Spencer. “Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle.” J Am Acad Child Adolesc Psychiatry 35 (1996): 409–32.

    Article  Google Scholar 

  11. See disclosure in A. Kotte. “Autistic traits in children with and without ADHD.” Pediatrics 132 (2013): e612–22.

    Article  Google Scholar 

  12. M. Smith. Small Comfort (New York: Praeger, 1985): 32.

    Google Scholar 

  13. IMS Health. “Top Therapeutic Classes by U.S. Dispensed Prescriptions,” 2012.

    Google Scholar 

  14. A. Horwitz. The Loss of Sadness (Oxford, NY: Oxford University Press, 2007): 53–104.

    Google Scholar 

  15. C. Silverman. The Epidemiology of Depression (Baltimore, MD: Johns Hopkins Press, 1968): 45–7.

    Google Scholar 

  16. D. Regier. “The de facto U.S. mental and addictive disorders service system.” Arch Gen Psychiatry 50 (1993): 85–94.

    Article  Google Scholar 

  17. R. Kessler. “Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey.” Arch Gen Psychiatry 51 (1994): 8–19.

    Article  Google Scholar 

  18. R. Hirschfeld. “The National Depressive and Manic-Depressive Association consensus statement on undertreatment of depression.” JAMA 277 (1997): 333–40.

    Article  Google Scholar 

  19. Scientific Therapeutics Information. “Paxil Advisory Board Meeting: A proposal for one psychiatrist advisory board meeting.” October 1, 1993. Accessed through Project on Government Oversight.

    Google Scholar 

  20. J Ballenger. “Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder.” Am J Psychiatry 155 (1998): 36–42.

    Article  Google Scholar 

  21. D. Sheehan. “The role of SSRIs in panic disorder.” J Clin Psychiatry 57, suppl. 10 (1996): 51–8.

    Google Scholar 

  22. D. Sheehan. “Current concepts in the treatment of panic disorder.” J Clin Psychiatry 60, suppl. 18 (1999): 16–21.

    Google Scholar 

  23. M. Liebowitz. “Social phobia. Review of a neglected anxiety disorder.” Arch Gen Psychiatry 42 (1985): 729–36.

    Article  Google Scholar 

  24. M. Pollack. “Introduction. New frontiers in the management of social anxiety disorder: diagnosis, treatment, and clinical course.” J Clin Psychiatry 60, suppl. 9 (1999): 3–8.

    Article  Google Scholar 

  25. M. Stein and M. Liebowitz. “Paroxetine treatment of generalized social phobia (social anxiety disorders): a randomized controlled trial.” JAMA 280 (1998): 708–13.

    Article  Google Scholar 

  26. M. Liebowitz. “Update on the diagnosis and treatment of social anxiety disorder.” J Clin Psychiatry 60, suppl. 18 (1999): 22–6.

    Article  Google Scholar 

  27. See Davidson’s disclosure in Hypericum Depression Trial Study Group. “Effect of Hypericum perforatum (St John’s Wort) in major depressive disorder.” JAMA 287 (2002): 1807–14.

    Article  Google Scholar 

  28. J. Davidson. “Introduction: new strategies for the treatment of posttraumatic stress disorder.” J Clin Psychiatry 61, suppl. 7 (2000): 3–4.

    Article  Google Scholar 

  29. Also see R. Hidalgo and J. Davidson. “Postraumatic stress disorder: epidemiology and health-related considerations.” J Clin Psychiatry 61, suppl. 7 (2000): 5–13.

    Google Scholar 

  30. J. Davidson. “Treatment of posttraumatic stress disorder: the impact of paroxetine.” Psychopharmacol Bull 37, suppl. 1 (2003): 76–88.

    Google Scholar 

  31. J. Ballenger. “Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety.” J Clin Psychiatry 62, suppl. 11 (2001): 53–8.

    Google Scholar 

  32. C. Nemeroff. “Advancing the treatment of mood and anxiety disorders.” Psychopharmacol Bull 37, suppl. 1 (2003): 6r–7.

    Google Scholar 

  33. R. Kessler. “Mood disorders in children and adolescents.” Biol Psychiatry 49 (2001): 1002–14.

    Article  Google Scholar 

  34. K. Merikangas. “Life prevalence of mental disorders in U.S. adolescents: Results from the National Comorbidity Study-Adolescent Supplement.” J Am Acad Child Adolesc Psychiatry 49 (2010): 980–9.

    Article  Google Scholar 

  35. M. Keller. “Depression in children and adolescents.” J Affect Disorders 21 (1991): 163–71.

    Article  Google Scholar 

  36. G. Emslie. “A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression.” Arch Gen Psychiatry 54 (1997): 1031–7.

    Article  Google Scholar 

  37. G. Emslie. “Mood disorders in children and adolescents.” Biol Psychiatry 49 (2001): 1082–90. Also see “Breakthroughs in the treatment of child and adolescent depression and anxiety,” newsletter produced by GSK in “Smith v. GSK,” accessed through DIDA.

    Article  Google Scholar 

  38. M. Goozner. “SSRI use in children: an industry-biased record.” Center for Science in the Publish Interest, February 2004.

    Google Scholar 

  39. T. Delate. “Trends in the use of antidepressants in a national sample of commercially insured pediatric patients, 1998 to 2002.” Psychiatr Serv 55 (2004): 387–91.

    Article  Google Scholar 

  40. T. Laughren, Memorandum. “Background comments for Feb. 2 meeting of psy-chopharmacological drugs advisory committee,” January 4, 2004. Accessed at fda.gov.

    Google Scholar 

  41. J. Leo. “The SSRI trials in children.” Ethical Human Psychology and Psychiatry 8 (2006): 29–41.

    Article  Google Scholar 

  42. E. Jane Garland. “Facing the evidence: antidepressant treatment in children and adolescents.” CMAJ 170 (February 17, 2004): 489–91. Also see Leo, ibid.

    Article  Google Scholar 

  43. J. Jureidini. “Clinical trials and drug promotion.” Int J Risk Saf Medicine 20 (2008): 73–81.

    Google Scholar 

  44. M. Keller. “Efficacy of paroxetine in the treatment of adolescent major depression.” J Am Acad Child Adolesc Psychiatry 40 (2001): 762–72.

    Article  Google Scholar 

  45. K. Wagner. “Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder.” JAMA 290 (2003): 1033–41. Also see Leo, ibid.

    Article  Google Scholar 

  46. D. Healy. “One flew over the conflict of interest net.” World Psychiatry 6 (2007): 26–7.

    Google Scholar 

  47. C. Silverman. The Epidemiology of Depression (Baltimore, MD: Johns Hopkins University Press, 1968): 35, 139. Given that in the studies of the 1940s and 1950s, fewer than 25 percent of the manic-depressive patients were of the manic or cycling types, at most 25 percent of the manic-depressive group in the hospital would have been of the bipolar type.

    Google Scholar 

  48. H. Akiskal. “Cyclothymic disorder: validating criteria for inclusion in the bipolar affective group.” Am J Psychiatry 134 (1977): 1227–33.

    Article  Google Scholar 

  49. H. Akiskal. “The prevalent clinical spectrum of bipolar disorders: beyond DSM-IV.” J Clin Psychopharmacol 16, 2 suppl. 1 (1996): 4S–14S.

    Article  Google Scholar 

  50. H Askiskal. “The emergence of the bipolar spectrum.” Psychopharmacol Bull 40 (2007): 99–115.

    Google Scholar 

  51. H. Akiskal. “Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders.” J Affect Disorders 59, suppl. 1 (2000): S5–S30.

    Article  Google Scholar 

  52. L. Judd. “The prevalence and disability of bipolar spectrum disorders in the US population.” J Affect Disorders 73 (2003): 123–31.

    Article  Google Scholar 

  53. H Akiskal. “The emergence of the bipolar spectrum.” Psychopharmacol Bull 40 (2007): 99–115.

    Google Scholar 

  54. See disclosure statement for Akiskal in G. Parker. “Issues for DSM-5: Whither melancholia? The case for its classification as a distinct mood disorder.” Am J Psychiatry 167 (2010): 745–7.

    Article  Google Scholar 

  55. G. Spielmans. “From evidence-based medicine to marketing-based medicine: Bioethic Inquiry.” J Bioethic Inq 7 (2010): 13–29.

    Article  Google Scholar 

  56. N. Ghaemi. “The failure to know what isn’t known: negative publication bias with lamotrigine and a glimpse inside peer review.” Evid Based Ment Health 12 (2009): 65–8.

    Article  Google Scholar 

  57. L. Cosgrove. “Tripartite conflicts of interest and high stakes patent extensions in the DSM-5.” Psychother Psychosom 83 (2014): 106–13.

    Article  Google Scholar 

  58. T. Insel. “Director’s blog: transforming diagnosis.” Published on nimh.nih.gov, April 29, 2013.

    Google Scholar 

  59. D. Regier. “DSM-5 field trials in the United States and Canada. Part II: test-retest reliability of selected categorical diagnoses.” Am J Psychiatry 170 (2013): 59–70.

    Article  Google Scholar 

  60. S. Vanheule. Diagnosis and the DSM: A Critical Review (New York, NY, Palgrave Macmillan, 2014): 40.

    Book  Google Scholar 

  61. J. Ronson. “Bipolar kids: victims of the ‘madness industry’?” New Scientist 2815, June 8, 2011: 44–7.

    Article  Google Scholar 

Download references

Authors
  1. Robert Whitaker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lisa Cosgrove
    View author publications

    You can also search for this author in PubMed Google Scholar

Copyright information

© 2015 Robert Whitaker and Lisa Cosgrove

About this chapter

Cite this chapter

Whitaker, R., Cosgrove, L. (2015). Expanding the Market. In: Psychiatry Under the Influence. Palgrave Macmillan, New York. https://doi.org/10.1057/9781137516022_6

Download citation

Publish with us

Policies and ethics

Search

Navigation